$ERNA
Eterna Therapeutics Inc.

2024 Q1 Form 10-K Financial Statement

#000114036124013254 Filed on March 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $47.00K $17.00K $68.00K
YoY Change
Cost Of Revenue $61.00K $66.00K $236.0K
YoY Change 22.0%
Gross Profit -$14.00K -$49.00K -$168.0K
YoY Change -72.0%
Gross Profit Margin -29.79% -288.24% -247.06%
Selling, General & Admin $4.315M $4.506M $14.59M
YoY Change 20.19% 62.09% -13.38%
% of Gross Profit
Research & Development $1.458M $1.210M $5.920M
YoY Change -12.9% -38.27% -43.03%
% of Gross Profit
Depreciation & Amortization $39.00K $24.00K $84.00K
YoY Change 85.71% 20.0% -47.83%
% of Gross Profit
Operating Expenses $5.773M $5.716M $20.97M
YoY Change 8.6% 20.59% -36.88%
Operating Profit -$5.787M -$5.765M -$21.14M
YoY Change 8.86% -36.37%
Interest Expense -$786.0K -$476.0K $614.0K
YoY Change 1472.0% 4660.0% -163.3%
% of Operating Profit
Other Income/Expense, Net -$856.0K $84.00K -$536.0K
YoY Change 801.05% -72.0% -106.17%
Pretax Income -$6.643M -$6.157M -$21.67M
YoY Change 22.77% 38.36% -11.67%
Income Tax $4.000K -$4.000K -$3.000K
% Of Pretax Income
Net Earnings -$6.600M -$6.161M -$21.70M
YoY Change 22.22% 36.91% -11.79%
Net Earnings / Revenue -14042.55% -36241.18% -31911.76%
Basic Earnings Per Share -$1.23 -$4.08
Diluted Earnings Per Share -$1.23 -$1.14 -$4.08
COMMON SHARES
Basic Shares Outstanding 5.410M 5.410M 5.314M
Diluted Shares Outstanding 5.410M 5.314M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.116M $7.575M $7.575M
YoY Change -5.26% -33.84% -33.84%
Cash & Equivalents $5.116M $7.575M
Short-Term Investments
Other Short-Term Assets $697.0K $1.599M $1.599M
YoY Change 48.3% 24.92% 24.92%
Inventory
Prepaid Expenses
Receivables $351.0K $425.0K $425.0K
Other Receivables $351.0K $425.0K $0.00
Total Short-Term Assets $6.164M $9.599M $9.599M
YoY Change -5.39% -29.84% -29.83%
LONG-TERM ASSETS
Property, Plant & Equipment $710.0K $493.0K $33.27M
YoY Change 230.23% 108.9% 2401.8%
Goodwill $2.000M $2.000M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $120.0K $120.0K $4.215M
YoY Change -90.34% -89.42% -19.41%
Total Long-Term Assets $43.49M $39.53M $39.53M
YoY Change 406.14% 359.79% 359.69%
TOTAL ASSETS
Total Short-Term Assets $6.164M $9.599M $9.599M
Total Long-Term Assets $43.49M $39.53M $39.53M
Total Assets $49.66M $49.13M $49.13M
YoY Change 228.68% 120.53% 120.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.063M $1.067M $1.067M
YoY Change 41.2% -34.14% -34.14%
Accrued Expenses $1.868M $1.893M $4.109M
YoY Change -7.16% -47.79% 4.82%
Deferred Revenue
YoY Change
Short-Term Debt $768.0K $1.205M $1.205M
YoY Change -56.11% -31.14% -31.14%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.768M $6.573M $6.573M
YoY Change 43.69% -14.12% -14.08%
LONG-TERM LIABILITIES
Long-Term Debt $8.014M $6.773M $6.773M
YoY Change 940.78% 459.75% 459.75%
Other Long-Term Liabilities $84.00K $33.55M $33.55M
YoY Change -3.45% 35594.68% 2461.3%
Total Long-Term Liabilities $84.00K $40.33M $40.33M
YoY Change -3.45% 42800.0% 1500.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.768M $6.573M $6.573M
Total Long-Term Liabilities $84.00K $40.33M $40.33M
Total Liabilities $53.07M $46.90M $46.90M
YoY Change 586.71% 361.06% 361.15%
SHAREHOLDERS EQUITY
Retained Earnings -$193.6M -$187.0M
YoY Change 13.42% 13.13%
Common Stock $27.00K $27.00K
YoY Change 3.85% 3.85%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.412M $2.233M $2.233M
YoY Change
Total Liabilities & Shareholders Equity $49.66M $49.13M $49.13M
YoY Change 228.68% 120.53% 120.52%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$6.600M -$6.161M -$21.70M
YoY Change 22.22% 36.91% -11.79%
Depreciation, Depletion And Amortization $39.00K $24.00K $84.00K
YoY Change 85.71% 20.0% -47.83%
Cash From Operating Activities -$3.700M -$4.658M -$20.40M
YoY Change -38.33% -14.37% -2.86%
INVESTING ACTIVITIES
Capital Expenditures $101.0K $19.00K $19.00K
YoY Change -5.0% -93.6%
Acquisitions
YoY Change
Other Investing Activities $4.000K $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$97.00K -$19.00K -$19.00K
YoY Change -114.62% -59.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.385M 7.706M 16.56M
YoY Change 1.53% -15.44%
NET CHANGE
Cash From Operating Activities -3.700M -4.658M -20.40M
Cash From Investing Activities -97.00K -19.00K -19.00K
Cash From Financing Activities 1.385M 7.706M 16.56M
Net Change In Cash -2.412M 3.029M -3.863M
YoY Change -59.8% 32.85% 163.15%
FREE CASH FLOW
Cash From Operating Activities -$3.700M -$4.658M -$20.40M
Capital Expenditures $101.0K $19.00K $19.00K
Free Cash Flow -$3.801M -$4.677M -$20.42M
YoY Change -36.65% -14.34% -4.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Cash
Cash
11446000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
425000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
951000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1599000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1284000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
9599000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4095000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
493000
CY2023Q4 us-gaap Goodwill
Goodwill
2044000
CY2022Q4 us-gaap Goodwill
Goodwill
2044000
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
0
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
59000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
120000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1134000
CY2023Q4 us-gaap Assets
Assets
49132000
CY2022Q4 us-gaap Assets
Assets
22279000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1067000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1620000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1893000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3626000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6573000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7654000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
116000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
331000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32854000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
887000
CY2023Q4 us-gaap Liabilities
Liabilities
46899000
CY2022Q4 us-gaap Liabilities
Liabilities
10172000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.005
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.005
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
156000
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
156000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
156000
CY2022Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
156000
CY2023Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
156000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.005
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.005
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5410000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5410000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5127000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5127000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
26000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
189186000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
177377000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165297000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2233000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12107000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49132000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22279000
CY2023 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5920000
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
10392000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14587000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16835000
CY2023 us-gaap Operating Expenses
OperatingExpenses
20967000
CY2022 erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
941000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-334000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1141000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-536000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8683000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21671000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
45000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-21668000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-24579000
CY2023 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
16000
CY2022 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
16000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21684000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24595000
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.08
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.08
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.06
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.06
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5314000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5314000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3051000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3051000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-21668000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-24579000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
84000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
161000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
2935000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1039000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
336000
CY2023 erna Gain Loss On Remeasurement Of Operating Lease Liability And Right Of Use Asset
GainLossOnRemeasurementOfOperatingLeaseLiabilityAndRightOfUseAsset
0
CY2022 erna Gain Loss On Remeasurement Of Operating Lease Liability And Right Of Use Asset
GainLossOnRemeasurementOfOperatingLeaseLiabilityAndRightOfUseAsset
642000
CY2023 us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
0
CY2022 us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
5990000
CY2023 erna Gain On Termination Of Lease
GainOnTerminationOfLease
0
CY2022 erna Gain On Termination Of Lease
GainOnTerminationOfLease
85000
CY2023 erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
59000
CY2022 erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
941000
CY2023 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-527000
CY2022 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
262000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
556000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
187000
CY2023 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1014000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
646000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2898000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2034000
CY2023 erna Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
1338000
CY2022 erna Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-340000
CY2023 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-374000
CY2022 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
155000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
297000
CY2023 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
250000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19706000
CY2023 erna Expenses Paid In Connection With Private Offering
ExpensesPaidInConnectionWithPrivateOffering
0
CY2022 erna Expenses Paid In Connection With Private Offering
ExpensesPaidInConnectionWithPrivateOffering
110000
CY2023 erna Issuance Of Common Stock From Exercise Of Pre Funded Warrants
IssuanceOfCommonStockFromExerciseOfPreFundedWarrants
0
CY2022 erna Issuance Of Common Stock From Exercise Of Pre Funded Warrants
IssuanceOfCommonStockFromExerciseOfPreFundedWarrants
7000
CY2023 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0
CY2022 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
5000
CY2023 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
16000
CY2022 us-gaap Payments Of Dividends Preferred Stock And Preference Stock
PaymentsOfDividendsPreferredStockAndPreferenceStock
16000
CY2023 erna Cash Paid For Fractional Shares In Connection With Reverse Stock Split
CashPaidForFractionalSharesInConnectionWithReverseStockSplit
0
CY2022 erna Cash Paid For Fractional Shares In Connection With Reverse Stock Split
CashPaidForFractionalSharesInConnectionWithReverseStockSplit
1000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16556000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19579000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3871000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1444000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15541000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16985000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11670000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15541000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
20000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
30000
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4000
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
15000
CY2023 erna Initial Measurement Of Finance Lease Liabilities
InitialMeasurementOfFinanceLeaseLiabilities
0
CY2022 erna Initial Measurement Of Finance Lease Liabilities
InitialMeasurementOfFinanceLeaseLiabilities
10000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7575000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11446000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11670000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15541000
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Concentration of Credit Risk</span></div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">The Company maintains its cash balances in financial institutions located in the United States. Accounts at each institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. The Company’s cash balances are uninsured for deposit accounts that exceed the FDIC insurance limit.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0);"> </span><br/> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">In the Company’s business, vendor concentrations could be indicative of vulnerabilities in the Company’s supply chain, which could ultimately impact the Company’s ability to continue its research and development activities. For the years ended December 31, 2023 and 2022, there was no vendor concentration related to the Company’s research and development activities.</div>
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0000748592
CY2023 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
500000
CY2023 us-gaap Open Tax Year
OpenTaxYear
2020 2021 2022 2023
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Auditor Firm
AuditorFirmId
248
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
1-11460
CY2023 dei Entity Registrant Name
EntityRegistrantName
Eterna Therapeutics Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
31-1103425
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
1035 Cambridge Street, Suite 18A,
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02141
CY2023 dei City Area Code
CityAreaCode
212
CY2023 dei Local Phone Number
LocalPhoneNumber
582-1199
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.005 par value
CY2023 dei Trading Symbol
TradingSymbol
ERNA
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
9700000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5410331
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Name
AuditorName
GRANT THORNTON LLP
CY2023 dei Auditor Location
AuditorLocation
New York, New York
CY2023Q4 us-gaap Cash
Cash
7575000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
13681000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
4095000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
236000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32781000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1030000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
2000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
0
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2216000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
295000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
190000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
6773000
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
392000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
0
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
107000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
156000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-186981000
CY2023 us-gaap Revenues
Revenues
68000
CY2022 us-gaap Revenues
Revenues
0
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
236000
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
0
CY2023 us-gaap Gross Profit
GrossProfit
-168000
CY2022 us-gaap Gross Profit
GrossProfit
0
CY2023 erna Research And Development In Process Asset Acquisition
ResearchAndDevelopmentInProcessAssetAcquisition
460000
CY2022 erna Research And Development In Process Asset Acquisition
ResearchAndDevelopmentInProcessAssetAcquisition
0
CY2023 us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
0
CY2022 us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
5990000
CY2022 us-gaap Operating Expenses
OperatingExpenses
33217000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-21135000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-33217000
CY2023 erna Warrant Liabilities Expense
WarrantLiabilitiesExpense
-215000
CY2022 erna Warrant Liabilities Expense
WarrantLiabilitiesExpense
-10795000
CY2023 erna Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
118000
CY2022 erna Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
0
CY2023 erna Loss On Non Controlling Investment
LossOnNonControllingInvestment
59000
CY2023 us-gaap Investment Income Net
InvestmentIncomeNet
138000
CY2022 us-gaap Investment Income Net
InvestmentIncomeNet
0
CY2023 us-gaap Interest Expense
InterestExpense
614000
CY2022 us-gaap Interest Expense
InterestExpense
30000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24534000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
25503000
CY2022 erna Stock Issued During Period Value Private Offering
StockIssuedDuringPeriodValuePrivateOffering
0
CY2022 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-5000
CY2022 erna Stock Issued During Period Value0f Common Stock And Warrants In Connection With Private Offering Net Of Offering Costs
StockIssuedDuringPeriodValue0fCommonStockAndWarrantsInConnectionWithPrivateOfferingNetOfOfferingCosts
7395000
CY2022 erna Stock Issued During Period Value Forfeiture Of Unvested Restricted Stock
StockIssuedDuringPeriodValueForfeitureOfUnvestedRestrictedStock
0
CY2022 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
16000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2935000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-24579000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12107000
CY2023 erna Stock Issued During Period Value Acquisitions2
StockIssuedDuringPeriodValueAcquisitions2
208000
CY2023 erna Stock Issued During Period Value Stock Purchase Agreement
StockIssuedDuringPeriodValueStockPurchaseAgreement
580000
CY2023 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
9014000
CY2023 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
766000
CY2023 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
16000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1242000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-21668000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2233000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
1242000
CY2023 erna Commitment Shares Issue Expense
CommitmentSharesIssueExpense
249000
CY2022 erna Commitment Shares Issue Expense
CommitmentSharesIssueExpense
0
CY2023 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
-11000
CY2022 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
0
CY2023 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2022 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
772000
CY2023 erna Non Cash Research And Development In Process Asset Acquisition
NonCashResearchAndDevelopmentInProcessAssetAcquisition
433000
CY2022 erna Non Cash Research And Development In Process Asset Acquisition
NonCashResearchAndDevelopmentInProcessAssetAcquisition
0
CY2023 erna Gain Loss On Disposal Of Fixed Assets
GainLossOnDisposalOfFixedAssets
1000
CY2022 erna Gain Loss On Disposal Of Fixed Assets
GainLossOnDisposalOfFixedAssets
280000
CY2023 us-gaap Interest Expense Debt
InterestExpenseDebt
176000
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
0
CY2023 us-gaap Paid In Kind Interest
PaidInKindInterest
113000
CY2022 us-gaap Paid In Kind Interest
PaidInKindInterest
0
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
303000
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-215000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-10795000
CY2023 erna Gain Loss On Change In Fair Value Of Contingent Consideration
GainLossOnChangeInFairValueOfContingentConsideration
-118000
CY2022 erna Gain Loss On Change In Fair Value Of Contingent Consideration
GainLossOnChangeInFairValueOfContingentConsideration
0
CY2023 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-1750000
CY2022 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
2956000
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
582000
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20408000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20976000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-47000
CY2023 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
16503000
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2023 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
251000
CY2022 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0
CY2023 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1500000
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
CY2023 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1500000
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
CY2023 erna Proceeds From Issuance Of Common Stock Pursuant To Stock Purchase Agreement
ProceedsFromIssuanceOfCommonStockPursuantToStockPurchaseAgreement
320000
CY2022 erna Proceeds From Issuance Of Common Stock Pursuant To Stock Purchase Agreement
ProceedsFromIssuanceOfCommonStockPursuantToStockPurchaseAgreement
0
CY2023 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2000
CY2023 erna Contingent Consideration For Asset Acquisition
ContingentConsiderationForAssetAcquisition
225000
CY2022 erna Contingent Consideration For Asset Acquisition
ContingentConsiderationForAssetAcquisition
0
CY2023 erna Issuance Of Common Stock For Asset Acquisition
IssuanceOfCommonStockForAssetAcquisition
208000
CY2022 erna Issuance Of Common Stock For Asset Acquisition
IssuanceOfCommonStockForAssetAcquisition
0
CY2023 erna Warrants Issued
WarrantsIssued
9219000
CY2022 erna Warrants Issued
WarrantsIssued
0
CY2023 erna Repricing Of Warrants In Connection With Financing
RepricingOfWarrantsInConnectionWithFinancing
766000
CY2022 erna Repricing Of Warrants In Connection With Financing
RepricingOfWarrantsInConnectionWithFinancing
0
CY2023 erna Unpaid Fees Incurred In Connection With The Issuance Of Convertible Notes And Warrants
UnpaidFeesIncurredInConnectionWithTheIssuanceOfConvertibleNotesAndWarrants
116000
CY2022 erna Unpaid Fees Incurred In Connection With The Issuance Of Convertible Notes And Warrants
UnpaidFeesIncurredInConnectionWithTheIssuanceOfConvertibleNotesAndWarrants
0
CY2023 erna Paid In Kind Interest Added To Convertible Notes Principal
PaidInKindInterestAddedToConvertibleNotesPrincipal
113000
CY2022 erna Paid In Kind Interest Added To Convertible Notes Principal
PaidInKindInterestAddedToConvertibleNotesPrincipal
0
CY2023 erna Initial Measurement Of Right Of Use Assets
InitialMeasurementOfRightOfUseAssets
34410000
CY2022 erna Initial Measurement Of Right Of Use Assets
InitialMeasurementOfRightOfUseAssets
1706000
CY2023 erna Initial Measurement Of Lease Liabilities
InitialMeasurementOfLeaseLiabilities
34170000
CY2022 erna Initial Measurement Of Lease Liabilities
InitialMeasurementOfLeaseLiabilities
1706000
CY2023 erna Adjustment To Lease Liability And Right Of Use Asset Due To Remeasurement
AdjustmentToLeaseLiabilityAndRightOfUseAssetDueToRemeasurement
-1620000
CY2022 erna Adjustment To Lease Liability And Right Of Use Asset Due To Remeasurement
AdjustmentToLeaseLiabilityAndRightOfUseAssetDueToRemeasurement
0
CY2023 erna Accrual For Purchases Of Property And Equipment
AccrualForPurchasesOfPropertyAndEquipment
323000
CY2022 erna Accrual For Purchases Of Property And Equipment
AccrualForPurchasesOfPropertyAndEquipment
0
CY2023 erna Conversion Of Warrant Liability To Equity
ConversionOfWarrantLiabilityToEquity
0
CY2022 erna Conversion Of Warrant Liability To Equity
ConversionOfWarrantLiabilityToEquity
867000
CY2023 erna Unpaid Fees Incurred In Connection With Private Offering
UnpaidFeesIncurredInConnectionWithPrivateOffering
0
CY2022 erna Unpaid Fees Incurred In Connection With Private Offering
UnpaidFeesIncurredInConnectionWithPrivateOffering
208000
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
4095000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
4095000
CY2023 erna Number Of In Licensed Portfolio Patents
NumberOfInLicensedPortfolioPatents
100
CY2023Q4 us-gaap Cash
Cash
7600000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-187000000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-21700000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20400000
CY2022Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
45500
CY2022Q4 us-gaap Line Of Credit
LineOfCredit
4100000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
4100000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Use of Estimates</span></div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="display:none;"><br/></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect: (a) the reported amounts of assets and liabilities; (b) disclosure of contingent assets and liabilities at the date of the consolidated financial statements; (c) the reported amounts of expenses during the reporting period; and (d) the reported amount of the fair value of assets acquired in connection with business combinations. On an ongoing basis, the Company evaluates its estimates, including those related to the recoverability and useful lives of long-lived assets; stock-based compensation assumptions; valuation assumptions of warrants; contingencies; contingent consideration and the provision for income taxes, including the valuation allowance. The Company bases its estimates on a combination of historical experience and various other assumptions that it believes are reasonable under the circumstances. Actual results may differ materially from these estimates.</div>
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
4100000
CY2023 erna Number Of Revenue Generating Contracts
NumberOfRevenueGeneratingContracts
1
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2023Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
600000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
100000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Derivatives Methods Of Accounting Nonhedging Derivatives
DerivativesMethodsOfAccountingNonhedgingDerivatives
<div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Warrants</span><br/> </div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;"> <br/> </span></div> <div style="display:none;"><br/></div> <div style="text-align: justify; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">The Company accounts for common stock warrants as either equity-classified or liability-classified instruments based on an assessment of the specific terms of the warrants and applicable authoritative guidance in ASC 480, <span style="font-style: italic;">Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging.</span> The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, or meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own stock and whether the holders of the warrants could potentially require net cash settlement in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.<span style="text-decoration: underline;"><br/> </span></div>
CY2023Q2 erna Allocated Percentage Of Fair Value Consideration To Purchased License
AllocatedPercentageOfFairValueConsiderationToPurchasedLicense
1
CY2023Q1 erna Proceeds From Option And License Agreement
ProceedsFromOptionAndLicenseAgreement
300000
CY2023 erna Proceeds From Cell Line Customization Activities
ProceedsFromCellLineCustomizationActivities
400000
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
1
CY2023 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2023 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Modification Of Contract
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract
0
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
100000
CY2023 erna Option Fee Obligation Payment Percentage
OptionFeeObligationPaymentPercentage
0.20
CY2023Q4 erna Effect Of Reduction Of Exercise Price Of Warrants
EffectOfReductionOfExercisePriceOfWarrants
1600000
CY2023Q4 erna Effect Of Reduction Of Exercise Price Of Warrants
EffectOfReductionOfExercisePriceOfWarrants
1600000
CY2023Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
21818000
CY2023Q3 erna Allocation Percentage Of Fair Value
AllocationPercentageOfFairValue
1
CY2023Q3 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
8715000
CY2023Q3 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
201000
CY2023Q3 erna Proceeds From Convertible Debt Net
ProceedsFromConvertibleDebtNet
8514000
CY2023Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
18554000
CY2023Q4 erna Allocation Percentage Of Fair Value
AllocationPercentageOfFairValue
1
CY2023Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
7788000
CY2023Q4 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
166000
CY2023Q4 erna Warrant Repricing
WarrantRepricing
1568000
CY2023Q4 erna Proceeds From Convertible Debt Net
ProceedsFromConvertibleDebtNet
6054000
CY2023 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
16503000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
10146000
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
303000
CY2023 erna Paid In Kind Interest Added To Convertible Notes Principal
PaidInKindInterestAddedToConvertibleNotesPrincipal
113000
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
6773000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
607000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
268000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
114000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
32000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
493000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
236000
CY2022 erna Gain Loss On Disposal Of Fixed Assets
GainLossOnDisposalOfFixedAssets
300000
CY2022Q4 erna Remaining Net Book Value Of Fixed Assets
RemainingNetBookValueOfFixedAssets
600000
CY2022 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
300000
CY2023 us-gaap Depreciation
Depreciation
100000
CY2022 us-gaap Depreciation
Depreciation
200000
CY2022Q1 erna Lessee Commitment To Purchase Property
LesseeCommitmentToPurchaseProperty
50000
CY2022Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
63000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1400000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1500000
CY2022 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
800000
CY2023Q4 erna Lease Liability Incremental Amount Above Tenant Improvement Allowance
LeaseLiabilityIncrementalAmountAboveTenantImprovementAllowance
600000
CY2023 erna Out Of Pocket Expenses
OutOfPocketExpenses
400000
CY2023Q4 erna Unpaid Out Of Pocket Costs Tenant Improvement Allowance
UnpaidOutOfPocketCostsTenantImprovementAllowance
1000000
CY2023 erna Adjustment To Lease Liability And Right Of Use Asset Due To Remeasurement
AdjustmentToLeaseLiabilityAndRightOfUseAssetDueToRemeasurement
-1600000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
3399000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
595000
CY2023 us-gaap Sublease Income
SubleaseIncome
84000
CY2022 us-gaap Sublease Income
SubleaseIncome
84000
CY2023 us-gaap Variable Lease Cost
VariableLeaseCost
136000
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
150000
CY2023 us-gaap Lease Cost
LeaseCost
3451000
CY2022 us-gaap Lease Cost
LeaseCost
661000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1030000
CY2023 erna Initial Measurement Of Operating Lease Rou Assets
InitialMeasurementOfOperatingLeaseROUAssets
34410000
CY2023 erna Adjustment To Remeasurement Of Operating Lease Rou Assets
AdjustmentToRemeasurementOfOperatingLeaseROUAssets
1620000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1039000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32781000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1182000
CY2023 erna Initial Measurement Of Operating Lease Liabilities
InitialMeasurementOfOperatingLeaseLiabilities
34169000
CY2023 erna Accretion Of Interest Sublease
AccretionOfInterestSublease
1858000
CY2023 erna Adjustment To Lease Liability Due To Remeasurement Of Sublease
AdjustmentToLeaseLiabilityDueToRemeasurementOfSublease
-1620000
CY2023 erna Principal Payments On Operating Lease Liabilities
PrincipalPaymentsOnOperatingLeaseLiabilities
519000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
35070000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32854000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2216000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y9M18D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1424
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6972000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6075000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6238000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6308000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
6406000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
33879000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
65878000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
30808000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
35070000
CY2019Q2 erna Area Of Sublease Space Currently Rented
AreaOfSubleaseSpaceCurrentlyRented
999
CY2019Q2 erna Percentage Of Lessee Sublease Increase In Annual Lease Rent Payments
PercentageOfLesseeSubleaseIncreaseInAnnualLeaseRentPayments
0.0225
CY2022 us-gaap Proceeds From Lease Payments
ProceedsFromLeasePayments
100000
CY2023 us-gaap Proceeds From Lease Payments
ProceedsFromLeasePayments
100000
CY2023Q4 erna Sale Leaseback Transactions Future Minimum Sublease Rentals Next Twelve Months
SaleLeasebackTransactionsFutureMinimumSubleaseRentalsNextTwelveMonths
86000
CY2023Q4 erna Sale Leaseback Transactions Future Minimum Sublease Rentals Within Two Years
SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinTwoYears
88000
CY2023Q4 erna Sale Leaseback Transactions Future Minimum Sublease Rentals Within Three Years
SaleLeasebackTransactionsFutureMinimumSubleaseRentalsWithinThreeYears
75000
CY2023Q4 erna Sale Leaseback Transactions Future Minimum Sublease Rentals
SaleLeasebackTransactionsFutureMinimumSubleaseRentals
249000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
100000
erna Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
0
CY2022Q4 us-gaap Goodwill
Goodwill
2000000
CY2023Q4 us-gaap Goodwill
Goodwill
2000000
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2018Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
6000000
CY2022 us-gaap Impairment Of Ongoing Project
ImpairmentOfOngoingProject
6000000
CY2022Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
0
CY2023 erna License Agreement Automatic Renewal Term
LicenseAgreementAutomaticRenewalTerm
P5Y
CY2023Q1 erna Percentage Of Sublicense Fees Paid Before License Expiration Date
PercentageOfSublicenseFeesPaidBeforeLicenseExpirationDate
0.20
CY2023Q1 erna Related Party Transaction Periodic Fees Payment Amount
RelatedPartyTransactionPeriodicFeesPaymentAmount
400000
CY2023 erna Notice Period For First Termination Of Contract
NoticePeriodForFirstTerminationOfContract
P120D
CY2022Q4 erna Payment Of Option Fee
PaymentOfOptionFee
250000
CY2023Q4 erna Accrued Legal Fees And Related Current
AccruedLegalFeesAndRelatedCurrent
643000
CY2022Q4 erna Accrued Legal Fees And Related Current
AccruedLegalFeesAndRelatedCurrent
1139000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
239000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
124000
CY2023Q4 erna Accrued Somerville Facility Current
AccruedSomervilleFacilityCurrent
218000
CY2022Q4 erna Accrued Somerville Facility Current
AccruedSomervilleFacilityCurrent
138000
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
176000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
109000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1065000
CY2023Q4 erna Accrued Clinical Current
AccruedClinicalCurrent
18000
CY2022Q4 erna Accrued Clinical Current
AccruedClinicalCurrent
570000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
490000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
590000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1893000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3626000
CY2022Q4 erna Litigation Settlement Amount Payable
LitigationSettlementAmountPayable
500000
CY2022 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
1200000
CY2023 erna Notice Period To Assume Control Patents
NoticePeriodToAssumeControlPatents
P30D
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21684000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24595000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5314000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5314000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3051000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3051000
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.08
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.08
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.06
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-17000
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.06
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27207000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5083000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1242000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2935000
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4713
CY2023 erna Class Of Warrant Or Right Grants In Period
ClassOfWarrantOrRightGrantsInPeriod
14209
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
18922
CY2022 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
0
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-21654000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-24513000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-21000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21671000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24534000
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
4000
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
0
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
4000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-2155000
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-6851000
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
8000
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1602000
CY2023 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-2000
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-187000
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2149000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-8640000
CY2023 erna Effective Income Tax Rate Reconciliation Decrease In Deferred Tax Assets Valuation Allowance Amount
EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount
2145000
CY2022 erna Effective Income Tax Rate Reconciliation Decrease In Deferred Tax Assets Valuation Allowance Amount
EffectiveIncomeTaxRateReconciliationDecreaseInDeferredTaxAssetsValuationAllowanceAmount
8681000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
45000
CY2023Q4 erna Deferred Tax Assets Operating Loss Carryforwards Excluding Foreign
DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign
12740000
CY2022Q4 erna Deferred Tax Assets Operating Loss Carryforwards Excluding Foreign
DeferredTaxAssetsOperatingLossCarryforwardsExcludingForeign
9382000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
784000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
782000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2141000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2173000
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1009000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1233000
CY2023Q4 erna Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
3105000
CY2022Q4 erna Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
1502000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
437000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
517000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
3000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences
81000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.0098
CY2023Q4 erna Deferred Tax Assets Right Of Use Liabilities
DeferredTaxAssetsRightOfUseLiabilities
8932000
CY2022Q4 erna Deferred Tax Assets Right Of Use Liabilities
DeferredTaxAssetsRightOfUseLiabilities
334000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
132000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Other
DeferredTaxAssetsTaxDeferredExpenseOther
549000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
29283000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
16553000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18302000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16157000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
10981000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
396000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
6000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
10000
CY2023Q4 erna Deferred Tax Assets Right Of Use Assets
DeferredTaxAssetsRightOfUseAssets
8349000
CY2022Q4 erna Deferred Tax Assets Right Of Use Assets
DeferredTaxAssetsRightOfUseAssets
291000
CY2023Q4 erna Deferred Tax Liabilities Convertible Debt
DeferredTaxLiabilitiesConvertibleDebt
2507000
CY2022Q4 erna Deferred Tax Liabilities Convertible Debt
DeferredTaxLiabilitiesConvertibleDebt
0
CY2023Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
179000
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Goodwill
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill
160000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
11041000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
461000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
60000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
65000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0492
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0652
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0001
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.0074
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.0609
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.099
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3538
CY2023 erna Effective Income Tax Rate Reconciliation Convertible Debt Percent
EffectiveIncomeTaxRateReconciliationConvertibleDebtPercent
-0.1192
CY2022 erna Effective Income Tax Rate Reconciliation Convertible Debt Percent
EffectiveIncomeTaxRateReconciliationConvertibleDebtPercent
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0
CY2023 erna Effective Income Tax Rate Reconciliation Uncertain Tax Positions Percent
EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent
-0
CY2022 erna Effective Income Tax Rate Reconciliation Uncertain Tax Positions Percent
EffectiveIncomeTaxRateReconciliationUncertainTaxPositionsPercent
0.0049
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.0334
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.0111
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0001
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0018
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
2100000
CY2023Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
400000
CY2022Q4 us-gaap Tax Credit Carryforward Amount
TaxCreditCarryforwardAmount
500000
CY2023 erna Tax Credit Carryforward Expiration Year
TaxCreditCarryforwardExpirationYear
2041
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
121000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
45000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
272000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
76000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
393000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
121000
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
0001140361-24-013254-index-headers.html Edgar Link pending
0001140361-24-013254-index.html Edgar Link pending
0001140361-24-013254.txt Edgar Link pending
0001140361-24-013254-xbrl.zip Edgar Link pending
ef20015352_10k.htm Edgar Link pending
ef20015352_ex10-13b.htm Edgar Link pending
ef20015352_ex10-13c.htm Edgar Link pending
ef20015352_ex10-14b.htm Edgar Link pending
ef20015352_ex10-14c.htm Edgar Link pending
ef20015352_ex10-16.htm Edgar Link pending
ef20015352_ex21-1.htm Edgar Link pending
ef20015352_ex23-1.htm Edgar Link pending
ef20015352_ex3-1.htm Edgar Link pending
ef20015352_ex31-1.htm Edgar Link pending
ef20015352_ex31-2.htm Edgar Link pending
ef20015352_ex32-1.htm Edgar Link pending
ef20015352_ex32-2.htm Edgar Link pending
ef20015352_ex97.htm Edgar Link pending
erna-20231231.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image00007.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
erna-20231231_def.xml Edgar Link unprocessable
erna-20231231_lab.xml Edgar Link unprocessable
ef20015352_10k_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
erna-20231231_cal.xml Edgar Link unprocessable
erna-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable